To test this hypothesis, we analyzed 9p24.1 gene dosage associations from WTS profiles with patient survival after ICT immunotherapy in a de-identified, RWC dataset of 894 HPV– HNSC patients with recurrent/metastatic disease: 208 patients received first- or second-line anti-PD-1 checkpoint therapy (pembrolizumab, nivolumab), and 694 patients had been treated with chemotherapy (with no prior or subsequent ICT). The gene discussed is PDCD1; the disease is metastatic neoplasm.